Core Insights - The article highlights significant year-on-year profit growth for various companies in the first three quarters, with some reporting exceptionally high increases in net profit [1] Group 1: Companies with Exceptional Profit Growth - Xinda Co., Ltd. expects a net profit increase of 2807.87%-3211.74% year-on-year [1] - Shenghe Resources anticipates a net profit growth of 696.82%-782.96% year-on-year [1] - Jiantou Energy projects a net profit rise of 231.75% year-on-year [1] - Batian Co., Ltd. forecasts a net profit increase of 230.79%-260.15% year-on-year [1] - Bai'ao Intelligent expects a net profit growth of 158.04%-210.20% year-on-year [1] Group 2: Companies with Notable Profit Increases - Tongxing Technology anticipates a net profit increase of 154.30%-233.77% year-on-year [1] - Ruixin Microelectronics projects a net profit growth of 116%-127% year-on-year [1] - Yahua Group expects a net profit increase of 106.97%-132.84% year-on-year [1] - Suihengyun A anticipates a net profit rise of 87.83%-180.38% year-on-year [1] - Taishan Petroleum projects a net profit increase of 87%-125% year-on-year [1] Group 3: Companies with Moderate Profit Growth - Shandong Gold anticipates a net profit increase of 83.9%-98.5% year-on-year [1] - Lutai A expects a net profit growth of 70.23%-84.12% year-on-year [1] - Zongshen Power projects a net profit increase of 70%-100% year-on-year [1] - Zijang Enterprises anticipates a net profit rise of 70%-90% year-on-year [1] - Jinjiang Shipping expects a net profit increase of 62.72%-66.89% year-on-year [1] Group 4: Companies with Lower but Positive Profit Growth - Jieshun Technology anticipates a net profit increase of 58.11%-86.01% year-on-year [1] - Gibit expects a net profit growth of 57%-86% year-on-year [1] - Xindong Link expects a net profit increase of 56.43%-91.19% year-on-year [1] - Tongda Co., Ltd. (rights protection) anticipates a net profit increase of 50.01%-111.12% year-on-year [1] - Dongwu Securities projects a net profit growth of 50%-65% year-on-year [1] Group 5: Companies Reporting Turnaround - Yuanda Intelligent (rights protection) expects a net profit of 33.83 million to 50.73 million, marking a turnaround [1] - Luoxin Pharmaceutical (rights protection) anticipates a net profit of 22.70 million to 25.20 million, indicating a turnaround [1] - Zhongke Sanhuan expects a net profit of 80 million to 100 million, also indicating a turnaround [1]

Core Viewpoint - Luoxin Pharmaceutical (002793.SZ) expects a net profit attributable to shareholders of 22.7 million to 25.2 million yuan for the first three quarters, marking a turnaround from losses year-on-year, with a net profit excluding non-recurring gains and losses of 4.7 million to 5.9 million yuan, also indicating a year-on-year turnaround [1] Group 1: Product Development - The commercialization process of the core innovative drug, Tegoprazan Tablets, has deepened, with the commercial team making significant progress in market expansion and access [1] - The product's terminal coverage in target markets has continuously expanded, leading to a significant year-on-year increase in sales, which has become a key driver of performance growth [1] Group 2: Financial Management - During the reporting period, the company has continuously optimized its working capital management [1] - The organization of special collection efforts for receivables has effectively improved the company's operating cash flow while reducing bad debt losses [1]

智通财经APP讯，罗欣药业(002793.SZ)披露2025年前三季度业绩预告，公司预计归属于上市公司股东的 净利润2270万元至2520万元，扭亏为盈;扣除非经常性损益后的净利润470万元至590万元。 ...

Core Viewpoint - 罗欣药业预计2025年前三季度实现归属净利润2270万元至2520万元，较上年同期的-2.65亿元有显著改善 [1] Group 1: Financial Performance - The company forecasts a net profit attributable to shareholders of approximately 22.7 million to 25.2 million yuan for the first three quarters of 2025, compared to a loss of 265 million yuan in the same period last year [1] Group 2: Product Development - The commercialization process of the core innovative drug,替戈拉生片, has deepened, with the commercial team making positive progress in market expansion and access [1] - The product's terminal coverage in target markets has continuously expanded, leading to a significant year-on-year increase in sales, which has become a key driver of performance growth [1] Group 3: Operational Efficiency - During the reporting period, the company has optimized its working capital management by organizing a special collection of receivables, effectively improving operating cash flow and reducing bad debt losses [1]

Group 1 - The core point of the article is that Luoxin Pharmaceutical (SZ 002793) expects to achieve a net profit of 22.7 million to 25.2 million yuan for the first three quarters of 2025, marking a turnaround from a loss in the previous year [1] - The basic earnings per share are projected to be between 0.0214 yuan and 0.0237 yuan, compared to a loss of 0.2486 yuan per share in the same period last year [1] - The main reason for the performance change is the deepening commercialization process of the core innovative drug, Tegoprazan tablets, which has seen significant sales growth due to market expansion efforts [1] - The company has improved its operating cash flow and reduced bad debt losses through effective management of accounts receivable [1] - For the first half of 2025, the revenue composition of Luoxin Pharmaceutical is expected to be 88.11% from pharmaceutical manufacturing, 10.1% from pharmaceutical commerce, and 1.79% from other businesses [1] Group 2 - As of the report date, Luoxin Pharmaceutical has a market capitalization of 5.3 billion yuan [2]

证券代码：002793 证券简称：罗欣药业 公告编号：2025-093 罗欣药业集团股份有限公司 2025年前三季度业绩预告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、本期业绩预计情况 1、业绩预告期间：2025 年 1 月 1 日至 2025 年 9 月 30 日。 2、业绩预告情况：预计净利润为正值且属于扭亏为盈情形 （1）2025 年前三季度预计业绩情况 单位：万元 | 项 目 | 本报告期 | | | 上年同期 | | --- | --- | --- | --- | --- | | 归属于上市公司股东的 净利润 | 2,270 | — | 2,520 | -26,537 | | 扣除非经常性损益后的 净利润 | 470 | — | 590 | -28,445 | | 基本每股收益（元/股） | 0.0214 | — | 0.0237 | -0.2486 | 二、与会计师事务所沟通情况 本业绩预告相关的财务数据未经会计师审计。公司就业绩预告已与会计师事 务所进行了预沟通，双方不存在分歧。 1 三、业绩变动原因说明 1、公司核心创新药产品替戈拉生 ...

Core Viewpoint - The appointment of Jiang Ying as the new Secretary of the Board at Luoxin Pharmaceutical marks a trend of fund managers transitioning into corporate governance roles, highlighting the increasing intersection between investment management and corporate leadership [1]. Company Summary - Luoxin Pharmaceutical announced the resignation of its Secretary of the Board, Han Fengsheng, due to job relocation, and appointed Jiang Ying, a former fund manager, as the new Secretary [1]. - Jiang Ying has a strong educational background with dual degrees in Science and Economics from Peking University, a Master's in Management from Peking University, and a Master's in Finance from the University of Hong Kong [2]. - Jiang Ying has four years of experience managing public funds, overseeing three fund products, including Guotai Jinniu Innovation Growth Mixed Fund, Guotai Science and Technology Innovation Board Two-Year Open Mixed Fund, and Guotai Small and Medium Cap Growth Mixed Fund [3]. Fund Management Performance - The funds managed by Jiang Ying have shown poor performance during her tenure, with returns of -7.01% for Guotai Jinniu Innovation Growth, -12.48% for Guotai Science and Technology Innovation Board Two-Year Open, and -34.28% for Guotai Small and Medium Cap Growth [4]. - The peak management scale reached 2.59 billion yuan in Q1 2022, but it has since declined, with Jiang Ying set to leave her last fund on December 24, 2024, for personal reasons [4]. Compensation and Future Outlook - The previous Secretary of the Board, Han Fengsheng, had an annual salary of 845,700 yuan, raising questions about Jiang Ying's future performance and compensation [5].

Core Viewpoint - The appointment of Jiang Ying as the new Secretary of the Board at Luoxin Pharmaceutical is a significant development, although her lack of experience in listed company secretary roles raises questions about her suitability for the position [3][6]. Company Overview - Luoxin Pharmaceutical, founded in 1988, has a diverse product range covering various medical fields including gastrointestinal diseases, pediatrics, oncology, and more [6]. - The company has experienced significant performance fluctuations in recent years, primarily due to the impacts of the COVID-19 pandemic, impairment provisions, and adjustments in financial liabilities [6]. Financial Performance - For the first half of 2025, Luoxin Pharmaceutical reported a revenue of 1.077 billion, a decrease of 14.45% year-on-year, while achieving a net profit attributable to shareholders of 17.695 million, marking a turnaround from losses in the previous year [6][7]. - The total revenue for the latest reporting period was 1.077 billion, with a total cost of 1.098 billion, resulting in an operating profit of 39.41 million, which is a 133.12% increase year-on-year [7]. - The net profit attributable to the parent company's shareholders was 17.695 million, reflecting a 119.95% increase compared to the same period last year [7]. Management Background - Jiang Ying, the newly appointed Secretary of the Board, has a strong academic background with dual degrees in Science and Economics from Peking University, as well as a Master's in Management from Peking University and a Master's in Finance from the University of Hong Kong [3][5]. - Prior to her appointment, Jiang Ying worked in various roles at Guotai Junan Securities, Everbright Pramerica Fund, and Guotai Fund, but lacks experience in listed company secretary positions [3][5].

罗欣药业集团股份有限公司 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002793 股票简称：罗欣药业 公告编号：2025-091 第五届董事会第三十一次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 一、董事会会议召开情况 2025年10月13日，罗欣药业集团股份有限公司（以下简称"公司"）第五届董事会第三十一次会议在山东 省临沂高新技术产业开发区罗七路管理中心三楼会议室和上海市浦东新区前滩世贸中心会议室以现场表 决和通讯表决相结合的方式召开。会议通知已于2025年10月10日以电话、专人送达、电子邮件等方式发 出。本次会议应出席董事5名，实际出席董事5名，公司监事、董事会秘书、拟受聘人员列席了会议。公 司董事长刘振腾先生主持了本次会议。会议的召集、召开符合《中华人民共和国公司法》等法律法规、 规范性文件和《罗欣药业集团股份有限公司章程》的规定，合法有效。 二、董事会会议审议情况 （一）审议通过《关于聘任董事会秘书的议案》 韩风生先生因工作调动原因申请辞去公司董事会秘书的职务，辞职后，继续在公司控股子公司山东罗欣 药业集团股份有 ...

【 导读 】 基金经理 转型 已 不局限在资管领域， 前国泰基金经理被聘为上市药企董秘 中国基金报记者 储是 10月13日， 罗欣药业发布关于聘任董事会秘书的公告， 显示 聘任姜英为董事会秘书。 公告未披露新任董秘姜英的 薪酬 情况， 前任董秘韩风生2024年薪酬为84.57万元 。 资料显示， 姜英 出生于 1987年，为 北京大学理学、经济学双学位本科，北京大学管理学硕 士及香港大学金融学硕士。 姜英 曾主要任职于国金证券资产管理分公司、光大保德信基金担 任分析师，于国泰基金担任分析师、基金经理助理、基金经理，无上市公司董秘工作经验。 | NEW YORK | 2 11 12 11 11 11 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 열매요이 | 代目 | 产品名称 | 特色同盟 | 田原田町 | NEED | 8000 | 年代回报 | 国际网站 | | 工作品 | 506000.01 | 国泰国际娱乐平台官 | 保障局合量 | 2002-02-18 | 2024-12-24 | -12-43% ...